Phosphodiesterase-5 Inhibitor PF-03049423 Effect on Stroke Recovery: A Double-Blind, Placebo-Controlled Randomized Clinical Trial.

Di Cesare, Franco; Mancuso, Jessica; Woodward, Phil; Bednar, Martin M; Loudon, Peter T

Di Cesare, Franco; Mancuso, Jessica; Woodward, Phil; Bednar, Martin M; Loudon, Peter T.

Affiliation

Di Cesare F; Leoben Research Limited, Glasgow, United Kingdom.
Mancuso J; Research Statistics, Pfizer, Groton, CT.
Woodward P; Research Statistics, Pfizer, Cambridge, United Kingdom.
Bednar MM; Neuroscience and Pain Research Unit, Pfizer, Cambridge, MA.
Loudon PT; Neuroscience and Pain Research Unit, Pfizer, Cambridge, United Kingdom. Electronic address: peter.t.loudon@Pfizer.com.

J Stroke Cerebrovasc Dis ; 25(3): 642-9, 2016 Mar.

Article in En | MEDLINE | ID: mdl-26738812

Subject(s)

Neuroprotective Agents/therapeutic use; Phosphodiesterase 5 Inhibitors/therapeutic use; Stroke/drug therapy; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Humans; International Cooperation; Male; Middle Aged; Pyrazines/therapeutic use; Pyridines/therapeutic use; Severity of Illness Index; Time Factors

Key words

PDE5; Stroke; clinical trial; neurorestoration

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neuroprotective Agents / Stroke / Phosphodiesterase 5 Inhibitors Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: J Stroke Cerebrovasc Dis Journal subject: ANGIOLOGIA / CEREBRO Year: 2016 Type: Article Affiliation country: United kingdom

Fulltext

XML

PubMed Links

Search on Google